[Watchlist](6/15 - 6/19/20) <$ISEE $VTVT $EVOK $ZSAN $GNUS $XSPA $MARK>
[Disclaimer]: I am not a professional, I expect you to do your own research and due diligence on any investment or trade that you may perform. None of the following is financial advice in any way shape or form. Trade at your own risk.
<$VTVT VTv Therapeutics, Inc (NASDAQ:VTVT) (Current Price: $2.80) (Float: 11.045M):> vTv Therapeutics Inc is located in the United States under the healthcare sector. Its main business model is the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease as well as treatments for Diabetes. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. For Diabetes you have TTP399, a type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
+ Over the weekend at the ADA Conference, vTv Therapeutics Presented Two Late-Breaking Poster Sessions on Simplici-T1 Study Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
<CHART TRADE>
<$ISEE IVERIC Bio, Inc (NASDAQ:ISEE) (Current Price: 3.9) (Float: 39.54:6M):> IVERIC Bio Inc is a United States based gene therapy focused company developing treatments for patients with orphan inherited retinal diseases with unmet medical needs. Its gene therapy is a technology that seeks to correct a faulty gene by providing a healthy gene replacement, through a single treatment, resulting in the expression of a therapeutic protein that was otherwise not being produced.
+ IVERIC bio is set to Announce Zimura:registered: 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020 at 8am EST
+ Block Trade: ISEE 696,106 @ $3.84 took place at 4:05pm Friday June 12th
The block trade on Friday only leads me to believe that someone knows something we don't about the results on this conference call and that they expect them to be very good, I mean that's over $2.6Million spent on a single trade. Follow. The. Money. Either way, with it being the Phase 3 results from an 18 month long clinical trial you can expect major price action in either direction depending on the news.
<CHART TRADE>
<$EVOK Evoke Pharma, Inc (NASDAQ:EVOK) (Current Price: $2.39) (Float: 23.729M):> Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. It's flagship product, Gimoti, is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. Currently metoclopramide tablets and injection are the only products approved in the United States to treat the symptoms associated with acute and recurrent diabetic gastroparesis.
+ Evoke Pharma Inc (NASDAQ:EVOK) has a PDUFA date for its Gimoti to treat women with acute and recurrent diabetic gastroparesis. (Friday)
The caveat here is that the FDA has already rejected Gimoti once before, Evoke the necessary changes and resubmitted it for this second time around. News here could go either way, be prepared.
<CHART TRADE>
<$ZSAN Zosano Pharma Copr (NASDAQ:ZSAN) (Current Price $0.90) (Float: 51.52M):> Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company only operating segment being developing human pharmaceutical products. All the business activities of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan delivered utilizing an Adhesive Dermally-Applied Microarray technology.
+ Zosano Pharma to Showcase New Post-hoc Analyses of Qtrypta's (M207) Clinical Trial Data Comparing Key Efficacy Results From the Pivotal Study and the Open-label Long Term Safety Study on the 2020 American Headache Society's Virtual Annual Scientific Meeting Platform. See attached file.
M207 can be used to treat migraines, which tends to be a price moving treatment.
<CHART TRADE>
<$GNUS Genius Brands International Inc (NASDAQ:GNUS) (Current Price: $4.17) (Float: 92.066M):> Genius Brands International Inc is a content and brand management company. It's a media company that creates and licenses animated multimedia entertainment content. The firm distributes its content in all formats as well as a broad range of consumer products based on its characters. In the children's media sector, its portfolio features content with a purpose for toddlers to tweens. This content includes baby genius, rainbow rangers, Netflix llama Llama, spacepop, Warren Buffett's secret millionaire's club, Thomas Edison's secret lab, and Stan Lee's cosmic crusaders. The company also acts as a licensing agent for certain brands, leveraging its existing licensing infrastructure. It generates a majority of its revenue from Television and Home Entertainment and Licensing and Royalties.
+ Over the weekend Kartoon Channel launched on several platforms with its official launch being Monday, June 16th. I already have this on my main TV and both of my kid's tablets and they are already addicted.
+ Off the SEC Filing Friday it looks to be that Genius Brands is gearing up for another offering, I wouldn't be surprised if it comes Monday or early this week.
I'm expecting a nice uptrend early Monday morning for some nice gains but I would sell early here, don't hold as the offering is coming. Dip buying off the offering however is going to be a fantastic chart trade and even swing opportunity.
<CHART or SWING TRADE>
<$MARK> <$XSPA> Both of these remain on my watchlist due to COVID-19 wave 2 incoming and the need for safety measures to be in place going forward throughout the world. Both companies have a proven product at this point and not some pump bullshit even though the stocks may be valued higher than they should be CURRENTLY. These are longterm/swings to me, however there is PLENTY of chart action and volatility to be had along the way.
<CHART or SWING TRADE>
<$NMHLY> <$WIMI> Notable mentions, if you know me or follow my watchlists, I don't need to write anything here.
Join now or log in to leave a comment